![](/img/cover-not-exists.png)
P845 ATLAS 1: the first Phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections
G.R. Corey, M.E. Stryjewski, W.D. O'Riordan, V.G. Fowler Jr, D.P. Ross, A. Hopkins, M.M. Kitt, S.L. BarriereVolume:
29
Year:
2007
Language:
english
DOI:
10.1016/s0924-8579(07)70686-6
File:
PDF, 86 KB
english, 2007